Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Metsera Inc. stock logo
MTSR
Metsera
$70.50
-0.4%
$64.53
$12.30
$83.86
$7.42BN/A4.84 million shs27.90 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$26.24
+1.5%
$26.82
$23.06
$28.75
$149.58B0.3541.49 million shs19.32 million shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Metsera Inc. stock logo
MTSR
Metsera
0.00%0.00%0.00%0.00%+158.24%
Pfizer Inc. stock logo
PFE
Pfizer
-0.23%+0.76%-4.24%-4.59%+10.83%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Metsera Inc. stock logo
MTSR
Metsera
$70.50
-0.4%
$64.53
$12.30
$83.86
$7.42BN/A4.84 million shs27.90 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$26.24
+1.5%
$26.82
$23.06
$28.75
$149.58B0.3541.49 million shs19.32 million shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Metsera Inc. stock logo
MTSR
Metsera
0.00%0.00%0.00%0.00%+158.24%
Pfizer Inc. stock logo
PFE
Pfizer
-0.23%+0.76%-4.24%-4.59%+10.83%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Metsera Inc. stock logo
MTSR
Metsera
2.33
Hold$55.75-20.92% Downside
Pfizer Inc. stock logo
PFE
Pfizer
2.19
Hold$28.619.06% Upside

Current Analyst Ratings Breakdown

Latest MTSR and PFE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/27/2026
Pfizer Inc. stock logo
PFE
Pfizer
Reiterated RatingNeutral
5/14/2026
Pfizer Inc. stock logo
PFE
Pfizer
Reiterated RatingUnderperform$26.00
5/6/2026
Pfizer Inc. stock logo
PFE
Pfizer
UpgradeHold (C-)Hold (C)
4/29/2026
Pfizer Inc. stock logo
PFE
Pfizer
Boost Price TargetNeutral$26.00 ➝ $27.00
4/20/2026
Pfizer Inc. stock logo
PFE
Pfizer
Reiterated RatingUnderperform$25.00
4/16/2026
Pfizer Inc. stock logo
PFE
Pfizer
Initiated CoverageOutperform$33.00
4/13/2026
Pfizer Inc. stock logo
PFE
Pfizer
Boost Price TargetNeutral$25.00 ➝ $27.00
4/10/2026
Pfizer Inc. stock logo
PFE
Pfizer
Boost Price TargetEqual Weight$27.00 ➝ $28.00
4/9/2026
Pfizer Inc. stock logo
PFE
Pfizer
Lower Price TargetNeutral$27.00 ➝ $26.00
3/24/2026
Pfizer Inc. stock logo
PFE
Pfizer
Boost Price TargetBuy$35.00 ➝ $36.00
(Data available from 5/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Metsera Inc. stock logo
MTSR
Metsera
N/AN/AN/AN/A$3.20 per shareN/A
Pfizer Inc. stock logo
PFE
Pfizer
$62.58B2.39$4.45 per share5.89$15.86 per share1.65
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Metsera Inc. stock logo
MTSR
Metsera
-$209.13M-$6.32N/AN/AN/AN/A-121.12%-53.54%N/A
Pfizer Inc. stock logo
PFE
Pfizer
$7.77B$1.3120.039.17N/A11.83%19.44%8.41%8/4/2026 (Estimated)

Latest MTSR and PFE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/5/2026Q1 2026
Pfizer Inc. stock logo
PFE
Pfizer
$0.7220$0.75+$0.0280$0.47$13.84 billion$14.45 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Metsera Inc. stock logo
MTSR
Metsera
N/AN/AN/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.56%-13.20%131.30%16 Years

Latest MTSR and PFE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/22/2026
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.436.71%5/8/20265/8/20266/12/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Metsera Inc. stock logo
MTSR
Metsera
N/A
4.25
5.26
Pfizer Inc. stock logo
PFE
Pfizer
0.67
1.25
0.94

Institutional Ownership

CompanyInstitutional Ownership
Metsera Inc. stock logo
MTSR
Metsera
N/A
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
Metsera Inc. stock logo
MTSR
Metsera
N/A
Pfizer Inc. stock logo
PFE
Pfizer
0.62%
CompanyEmployeesShares OutstandingFree FloatOptionable
Metsera Inc. stock logo
MTSR
Metsera
81105.29 millionN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
75,0005.70 billion5.66 billionOptionable

Recent News About These Companies

3 Dividend Stocks Yielding Above 5% to Scoop Up Now
Thinning revenues: inside the $14bn Eliquis patent cliff
If Viking Therapeutics Is Acquired, Here's Who Wins
Arnhold LLC Raises Stock Holdings in Pfizer Inc. $PFE

New MarketBeat Followers Over Time

Media Sentiment Over Time

Metsera stock logo

Metsera NASDAQ:MTSR

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.

Pfizer stock logo

Pfizer NYSE:PFE

$26.24 +0.39 (+1.49%)
As of 12:59 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.